Search Results for:

Alvotech and AbbVie Settle Patent Dispute

Alvotech Holdings S.A. (“Alvotech”) has announced that they have settled all pending disputes between AbbVie and Alvotech related to AVT02 (100mg/mL), Alvotech’s high-concentration, citrate-free biosimilar candidate for Humira® (adalimumab). The announcement states that under the settlement agreement, Alvotech has non-exclusive rights to market AVT02 in the United States starting July…

Read More

Adalimumab biosimilar wins NMPA approval

Shanghai Junshi Biosciences Co. Ltd. and Mabwell Bioscience Co. Ltd. announced that the jointly developed adalimumab biosimilar injection (Junmaikang ®) was officially approved by the Chinese National Medical Products Administration (NMPA) for marketing authorization (drug approval number: Sinopharm S20220008). Junmaikang® is used for the treatment of rheumatoid arthritis, ankylosing spondylitis,…

Read More